38: The selective IF channel antagonist Ivabradine in stable patients after heart transplantation (HTX)

benefit were calculated for each group separately. Results: Patients were grouped at listing as: non-Amb (123,20%), high (164,27%), moderate (181,30%) & low risk HFSS (142,23%). Mean age was 47 yrs (SD 11), with 83% male, common diagnoses were IHD (44%) & dilated cardiomyopathy (43%). In Amb-HF patients, peak VO2 was 12 (SD 4) ml/Kg/min. Most non-Amb patients had inotropic support (79%) &/or IABP (33%). Almost 80% of non-Amb group had HTx within a year of listing, compared to approx /3 of Amb-HF group (median wait 8 vs 90 days respectively). Probability of dying within a year while waiting was greatest for the non-Amb group (16%) & lowest for the low risk HFSS patients (6%). Survival after HTx did not differ between the groups.